Dianthus Therapeutics, Inc. /DE/ - 10-Q Filing

Dianthus Therapeutics reports Q3 2026 financial results featuring milestone payments from Iontas Limited and ongoing R&D activities.

SEC EDGAR ·

Tickers: $DNTH

Read the full article at SEC EDGAR

More Regulatory news